MedTrace Logo

Protective Antibody Level After COVID-19 Vaccination Among Patients Under Hemodialysis

NCT04871945 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 31

Last updated 2022-03-17

No results posted yet for this study

Summary

The aim of the study is to evaluate the level of neutralizing antibody against SARS-CoV-2 after COVID-19 vaccination in patients under hemodialysis. To this end, the level of neutralizing antibody of patients under hemodialysis is compared to that of healthy population.

Conditions

  • Covid19
  • Vaccine Reaction
  • Hemolysis
  • End-stage Renal Disease

Interventions

DIAGNOSTIC_TEST

Elecsys Anti-SARS-CoV-2 S (Roche Diagnostics GmbH, Mannheim, Germany), 2) ACCESS SARS-CoV-2 IgG II (Beckman Coulter, Inc. USA)

The antibody level will be measured by the above mentioned methods. The trial drugs are not used but the vaccine that included in National Immunization Program for COVID-19 in Korea will be used for the study.

Sponsors & Collaborators

  • Seegene Medical Foundation

    collaborator UNKNOWN

  • Hanyang University Seoul Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-20
Primary Completion
2021-09-30
Completion
2021-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04871945 on ClinicalTrials.gov